Cellectar Biosciences
CLRB
31 hedge funds and large institutions have $3.65M invested in Cellectar Biosciences in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 30 → 31 (+1)
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
22% less capital invested
Capital invested by funds: $4.69M → $3.65M (-$1.04M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$32.9K |
| 2 |
Renaissance Technologies
New York
|
+$18.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11K |
| 4 |
VF
Virtu Financial
New York
|
+$7.28K |
| 5 |
Jane Street
New York
|
+$6.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1WM
1900 Wealth Management
San Antonio,
Texas
|
-$83K |
| 2 |
BlackRock
New York
|
-$65.8K |
| 3 |
SCM
Sterneck Capital Management
Kansas City,
Missouri
|
-$21K |
| 4 |
Franklin Resources
San Mateo,
California
|
-$18.6K |
| 5 |
Two Sigma Advisers
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JFGIW
26
Johnson Financial Group Inc (Wisconsin)
Racine,
Wisconsin
| $2K | – | – | – |
|
27
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
IA
28
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
29
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
30
Bank of America
Charlotte,
North Carolina
| $1K | +$714 | +5 | New |
|
|
1WM
31
1900 Wealth Management
San Antonio,
Texas
| – | -$83K | -400 | Closed |
|
|
SCM
32
Sterneck Capital Management
Kansas City,
Missouri
| – | -$21K | -100 | Closed |
|
|
33
Two Sigma Advisers
New York
| – | -$7K | -36 | Closed |
|
CLRB Hedge Fund Activity: Q2 2022 in Review
31 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2022, worth a combined $3.65M — down 22% from $4.69M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CLRB positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $32.9K. The largest seller was 1900 Wealth Management, exiting entirely with an estimated $83K sold.
- 31 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2022, up from 30 in Q1 2022.
- Funds reported $3.65M of Cellectar Biosciences stock for Q2 2022, down 22% quarter-over-quarter.
- 4 funds opened new Cellectar Biosciences positions in Q2 2022 and 3 closed out, a net change of +1 holder.
- The largest Cellectar Biosciences buyer in Q2 2022 was Citadel Advisors, an estimated $32.9K added.
- The largest Cellectar Biosciences seller in Q2 2022 was 1900 Wealth Management, an estimated $83K sold.
Based on aggregated 13F filings for Q2 2022.